ANN ARBOR, Mich, May 12, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three months ended March 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented… Read More..

Company Reports Breakeven Results on Revenue of ~$4.4 Million SAN FRANCISCO, CA, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for… Read More..

KZR-616 clinical development in three severe autoimmune diseases is advancing with several data readouts expected in 2021 and 2022 KZR-261 IND submission expected mid-2021, with Phase 1 trial in solid tumors expected to initiate before year-end Cash, cash equivalents and marketable securities of $142 million as of March 31, 2021… Read More..